Latigo director reports no insider holdings

Latigo Biotherapeutics, Inc. (LTGO) had an initial Form 3 beneficial ownership report filed by Kevin Raidy, who is identified as a director of the company.

Accepted by SEC EDGAR 08/06/2026 - 08:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Latigo Biotherapeutics, Inc. (LTGO) had an initial Form 3 beneficial ownership report filed by Kevin Raidy, who is identified as a director of the company. The filing lists no reportable transactions or holdings, indicating that no equity positions are being reported at this time.

Key Figures

Buy transactions: 0 Sell transactions: 0 Net buy/sell shares: 0 +2 more

5 metrics

Buy transactions 0 Number of buy transactions reported for Kevin Raidy on this Form 3

Sell transactions 0 Number of sell transactions reported for Kevin Raidy on this Form 3

Net buy/sell shares 0 Net buy or sell share count reported in the transaction summary

Holding entries 0 Number of non-derivative or derivative holding entries reported

Derivative transactions 0 Total derivative transaction count in the transaction summary

Key Terms

Form 3, beneficial ownership, derivative securities

3 terms

Form 3 regulatory

"an initial <b>Form 3</b> beneficial ownership report filed by Kevin Raidy"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"an initial Form 3 <b>beneficial ownership</b> report filed by Kevin Raidy"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

derivative securities financial

"No <b>derivative securities</b> are reported. The derivativeSummary is empty"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the LTGO Form 3 filed by Kevin Raidy report?

The Form 3 for LTGO reports that director Kevin Raidy has no reportable equity holdings or transactions. It is an initial statement of beneficial ownership with all transaction and holding counts shown as zero.

Is Kevin Raidy a director or officer of Latigo Biotherapeutics, Inc. (LTGO)?

The filing identifies Kevin Raidy as a director of Latigo Biotherapeutics, Inc. He is not reported as an officer, ten percent owner, or in any other role on this Form 3.

Does the LTGO Form 3 show any insider buy or sell transactions?

No. The Form 3 for LTGO shows zero buy, sell, acquire, dispose, or other transactions. All transaction-related counts, including net buy/sell shares, are reported as 0.

Are there any derivative securities reported for LTGO on this Form 3?

No derivative securities are reported. The derivativeSummary is empty and the filing lists 0 derivative transactions and 0 exercise events, indicating no options or similar instruments disclosed here.

Does the LTGO Form 3 indicate use of a Rule 10b5-1 trading plan?

No. The Form 3 data show the Rule 10b5-1 plan indicator as null, and there are no footnote disclosures about trading plans. Since there are no transactions, trading-plan status is not a factor in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Raidy Kevin

(Last) (First) (Middle)

C/O LATIGO BIOTHERAPEUTICS, INC.

1300 RANCHO CONEJO BLVD., SUITE 305

(Street)

THOUSAND OAKS CALIFORNIA 91320

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/06/2026

3. Issuer Name and Ticker or Trading Symbol
Latigo Biotherapeutics, Inc. [ LTGO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Sabrina Nieder, Attorney-in-Fact	08/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)